Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188831 | 0.86 | HTR2A (0.72) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL13176112 | 0.84 | HTR2A (0.73) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL13995387 | 0.82 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL13995368 | 0.81 | HTR2A (0.62) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL9303072 | 0.81 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4742374 | 0.80 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL19563418 | 0.80 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4159760 | 0.79 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL23884744 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL12169379 | 0.77 | HTR2A (0.72) | ALDH1A1MEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-7888383-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| EP-2268281-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20090221578-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | disclosed |
| WO-2009102462-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1971574-A2 | BICYCLIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY OR ANTIALLERGIC AGENTS | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007065684-A2 | BICYCLIC HETEROYCLIC COMPOUNDS AS ANTIINFLAMMATORY OR ANTIALLERGIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-5314880-A | Platelet activating factor antagonist | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-05-24 | — | — | US | disclosed |
| WO-1993015047-A1 | AMINO ACID DERIVATIVES AS PAF ANTAGONISTS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0468971-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990009997-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | ALDH1A1 837/4885MEN1 4412/4885KMT2A 3711/4885 |
| US-20090221578-A1 | Organic Compounds | DRD4, RDX, DRD1 | ALDH1A1 723/4885MEN1 674/4885KMT2A 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.